Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
Drug deliveryâs next bottleneck isnât innovation, itâs industrial capacity
Drug deliveryâs next bottleneck is manufacturing capacity: scale, validation, and resilient supply chains.
Read Full Article
Pharma Tech
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
The agreement will see Sanofi and Regeneron co-develop and co-commercialise four long-lasting antibodies.
Read Full Article
Pharma Tech
Varda pockets $251m to back space-based pharma processing missionÂ
Varda secures this capital as drugmakers tout the potential of manufacturing in microgravity conditions to create differentiated medicines.
Read Full Article
Express Pharma
9th Edition PURIFY26 â Chromatography Purification Conclave for thought provoking leadership
In addition to deep technical sessions, the conclave serves as a primary networking hub in India for Heads of analytical and research, scale-up, production, kilo labs, supply chain, policy makers, and academic leaders. The post 9th Edition PURIFY26 â Chromatography Purification Conclave for thought provoking leadership appeared first on Express Pharma.
Read Full Article
Pharma Tech
Bristol Myers Squibb secures expanded US approval for Camzyos
The US FDA has expanded the approved indication for BMS' Camzyos to treat symptomatic oHCM in adults and paediatric patients weighing at least 30 kg.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
ET Pharma
Oct 1, 2026, 8:18 PM
âIndiaâs biotech ecosystem holds tremendous promiseâ: Eli Lilly CEO
Eli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadership in anti-obesity drugs through ongoing innovation and development. With successful trials for drugs like retatrutide and Foundayo, Lilly is expanding its product offerings. The company recognizes the importance of India as a growing market for healthcare investments and partnerships.
PharmaShots
Oct 1, 2026, 1:38 PM
How Does SIGMAR1 Recombinant Protein Help Study Alzheimerâs Disease?
Neurons are specialized nerve cells in the brain and nervous system that continuously communicate. At the same time, our brain produces and clears proteins, mitochondria generate energy, and the endoplasmic reticulum (ER) maintains protein and calcium balance. These processes work together to keep neurons healthy and functioning properly. However, when this cellular balance is disrupted,⌠The post How Does SIGMAR1 Recombinant Protein Help Study Alzheimerâs Disease? appeared first on PharmaShots.
PharmaShots
Oct 1, 2026, 12:30 PM
BI Reports P-III (SYNCHRONIZE-2) Trial Data on Survodutide for Obesity/Overweight and Type 2 Diabetes at EASD 2026
Shots: Ref: Globenewswire |  Image: Boehringer Ingelheim  | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post BI Reports P-III (SYNCHRONIZE-2) Trial Data on Survodutide for Obesity/Overweight and Type 2 Diabetes at EASD 2026 appeared first on PharmaShots.
Pharma Tech
Oct 1, 2026, 11:30 AM
Drug deliveryâs next bottleneck isnât innovation, itâs industrial capacity
Drug deliveryâs next bottleneck is manufacturing capacity: scale, validation, and resilient supply chains.
PharmaShots
Oct 1, 2026, 11:30 AM
BMS Reports US FDA Approval of Camzyos in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Shots: Ref: Businesswire |  Image: BMS  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post BMS Reports US FDA Approval of Camzyos in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) appeared first on PharmaShots.
PharmaShots
Oct 1, 2026, 10:51 AM
Q3 2026 Biopharma Review: Mega Deals, Strategic Licensing, and a Wave of FDA InnovationÂ
Introduction The third quarter of 2026 underscored just how rapidly the biopharma landscape is being reshaped by capital, innovation, and strategic consolidation. Across July through September, the industry saw a succession of multibillion-dollar acquisitions, high-value licensing agreements, and a broad spectrum of FDA approvals spanning oncology, rare diseases, metabolic disorders, neurology, immunology, and precision diagnostics. ⌠The post Q3 2026 Biopharma Review: Mega Deals, Strategic Licensing, and a Wave of FDA Innovation appeared first on PharmaShots.
News
Latest industry coverage
Google News
Oct 1, 2026, 8:32 PM
HRSA approves 10 drug companies for participation in the 340B Rebate Model Pilot Program - American Hospital Association
HRSA approves 10 drug companies for participation in the 340B Rebate Model Pilot Program  American Hospital Association
Google News
Oct 1, 2026, 8:27 PM
Agilent Introduces NovoStation Sample Prep System to Automate Flow Cytometry Workflows - Contract Pharma
Agilent Introduces NovoStation Sample Prep System to Automate Flow Cytometry Workflows  Contract Pharma
Google News
Oct 1, 2026, 7:57 PM
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST) - Yahoo Finance
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)Â Â Yahoo Finance
Google News
Oct 1, 2026, 7:37 PM
Varda raises $251 million to expand drug manufacturing in space - The Pharma Letter
Varda raises $251 million to expand drug manufacturing in space  The Pharma Letter
Google News
Oct 1, 2026, 7:35 PM
âIndiaâs biotech ecosystem holds tremendous promiseâ: Eli Lilly CEO - The Economic Times
âIndiaâs biotech ecosystem holds tremendous promiseâ: Eli Lilly CEOÂ Â The Economic Times
Google News
Oct 1, 2026, 7:27 PM
Vir Biotechnology Appoints Aziz Sawaf As CFO - Pulse 2.0
Vir Biotechnology Appoints Aziz Sawaf As CFOÂ Â Pulse 2.0
Google News
Oct 1, 2026, 7:24 PM
"Patient-centric innovation must be central mission of life sciences industry": JP Nadda at BLSA awards - ANI News
"Patient-centric innovation must be central mission of life sciences industry": JP Nadda at BLSA awards  ANI News
Google News
Oct 1, 2026, 7:15 PM
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know - TradingKey
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know  TradingKey
Google News
Oct 1, 2026, 7:02 PM
Cronus Pharma Announces the Launch of Florfinasone⢠Otic for the Treatment of Otitis Externa in Dogs - Business Wire
Cronus Pharma Announces the Launch of Florfinasone⢠Otic for the Treatment of Otitis Externa in Dogs  Business Wire
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer